High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.

Sims, Emily K; Geyer, Susan M; Long, S Alice; Herold, Kevan C

Sims, Emily K; Geyer, Susan M; Long, S Alice; Herold, Kevan C.

Afiliación

Sims EK; Division of Pediatric Endocrinology and Diabetology and Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Geyer SM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Long SA; Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, USA.
Herold KC; Department of Immunobiology, Yale University, New Haven, CT, USA. Kevan.Herold@yale.edu.

Diabetologia ; 66(12): 2283-2291, 2023 12.

Article en En | MEDLINE | ID: mdl-37667106

Asunto(s)

Diabetes Mellitus Tipo 1; Proinsulina; Humanos; Péptido C; Anticuerpos Monoclonales Humanizados/uso terapéutico; Insulina/metabolismo

Palabras clave

Beta cell; Beta cell dysfunction; Beta cell stress; Biomarker; Precision medicine; Proinsulin; Teplizumab; Type 1 diabetes; Type 1 diabetes prevention

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proinsulina / Diabetes Mellitus Tipo 1 Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Risk_factors_studies Idioma: En Revista: Diabetologia Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google